Education
About Us
Working with TipRanks
Follow Us
Rocket Pharmaceuticals (RCKT)
NASDAQ:RCKT
RCKT Analyst Ratings
Strong Buy
14 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
RCKT Stock 12 Month Forecast
Average Price Target
$42.00
▲(529.69% Upside)
| Highest Price Target$55.00 | Average Price Target$42.00 | Lowest Price Target$15.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Cantor Fitzgerald
Reiterated
03/24/25
BMO Capital
Initiated
03/11/25
Scotiabank
Reiterated
03/03/25
Chardan Capital
Reiterated
02/28/25
J.P. Morgan
Reiterated
02/28/25
Bank of America Securities
Reiterated
02/28/25
Goldman Sachs
Reiterated
02/28/25
William Blair
Reiterated
02/28/25
Canaccord Genuity
Reiterated
02/28/25
LifeSci Capital
Reiterated
02/28/25
TD Cowen
―
Buy
―
Reiterated
02/28/25
Promising Pipeline and Market Opportunities Drive Buy Rating for Rocket Pharmaceuticals
Morgan Stanley
$42
Buy
529.69%
Upside
Reiterated
02/28/25
Morgan Stanley Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT)
Wedbush
$32
Buy
379.76%
Upside
Reiterated
02/28/25
Promising Outlook for Rocket Pharmaceuticals: Buy Rating Reiterated with $32 Price Target
Needham
$42
Buy
529.69%
Upside
Reiterated
02/28/25
Positive Outlook for Rocket Pharmaceuticals Amidst Regulatory Progress and Financial Stability
Leerink Partners
$40→$39
Buy
484.71%
Upside
Reiterated
02/27/25
Promising Pipeline and Financial Stability Drive Buy Rating for Rocket Pharmaceuticals
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Cantor Fitzgerald
Reiterated
03/24/25
BMO Capital
Initiated
03/11/25
Scotiabank
Reiterated
03/03/25
Chardan Capital
Reiterated
02/28/25
J.P. Morgan
Reiterated
02/28/25
Bank of America Securities
Reiterated
02/28/25
Goldman Sachs
Reiterated
02/28/25
William Blair
Reiterated
02/28/25
Canaccord Genuity
Reiterated
02/28/25
LifeSci Capital
Reiterated
02/28/25
TD Cowen
―
Buy
―
Reiterated
02/28/25
Promising Pipeline and Market Opportunities Drive Buy Rating for Rocket Pharmaceuticals
Morgan Stanley
$42
Buy
529.69%
Upside
Reiterated
02/28/25
Morgan Stanley Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT)
Wedbush
$32
Buy
379.76%
Upside
Reiterated
02/28/25
Promising Outlook for Rocket Pharmaceuticals: Buy Rating Reiterated with $32 Price Target
Needham
$42
Buy
529.69%
Upside
Reiterated
02/28/25
Positive Outlook for Rocket Pharmaceuticals Amidst Regulatory Progress and Financial Stability
Leerink Partners
$40→$39
Buy
484.71%
Upside
Reiterated
02/27/25
Promising Pipeline and Financial Stability Drive Buy Rating for Rocket Pharmaceuticals
RCKT Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
23
22
25
18
17
Buy
7
5
5
2
2
Hold
1
1
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
31
28
31
21
20
Each month's total comprises the sum of three months' worth of ratings.
RCKT Financial Forecast
RCKT Stock Forecast FAQ
What is RCKT’s average 12-month price target, according to analysts?
Based on analyst ratings, Rocket Pharmaceuticals’s 12-month average price target is $42.00.
What is RCKT’s upside potential, based on the analysts’ average price target?
Rocket Pharmaceuticals has 529.69% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is RCKT a Buy, Sell or Hold?
Rocket Pharmaceuticals has a consensus rating of Strong Buy which is based on 14 buy ratings, 1 hold ratings and 0 sell ratings.
What is Rocket Pharmaceuticals’s price target?
The average price target for Rocket Pharmaceuticals is $42.00. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $55.00 ,the lowest forecast is $15.00. The average price target represents 529.69% Increase from the current price of $6.67.
The highest analyst price target is $55.00 ,the lowest forecast is $15.00. The average price target represents 529.69% Increase from the current price of $6.67.
What do analysts say about Rocket Pharmaceuticals?
Rocket Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
How can I buy shares of RCKT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.